Pilot: Finasteride Treatment for Chronic Central Serous Chorioretinopathy

试点：非那雄胺治疗慢性中心性浆液性脉络膜视网膜病变

• 批准号: 7976122
• 负责人: DARBY THOMPSON
• 金额: $ 7.97万
• 依托单位: THE EMMES COMPANY, LLC
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-11-01 至 2011-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7976122
• 关键词: Pilot; Finasteride; Treatment; Chronic; Central

Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Central serous chorioretinopathy (CSCR) is a disease of the retina that is caused by an accumulation of fluid under the retina. It affects the macula, the central part of the retina needed for sharp, clear vision and activities such as reading, sewing, and driving. In many cases, CSCR resolves on its own and does not require treatment. In some patients, however, the disease does not resolve or recurs, which is called chronic CSCR. - Chronic CSCR may be caused in part by hormones called androgens. Finasteride is a drug that can block the effects of androgens. Objectives: - To evaluate whether finasteride is safe to give to people with chronic CSCR. - To evaluate whether finasteride can help preserve vision in patients with chronic CSCR. - To determine whether future trials with finasteride are needed in patients with chronic CSCR.

芬必得治疗慢性中心性浆液性脉络膜视网膜病变的初步研究 中心性浆液性脉络膜视网膜病变（CSCR）是由视网膜下液体积聚引起的视网膜疾病。它影响黄斑，视网膜的中心部分，需要敏锐，清晰的视觉和活动，如阅读，缝纫和驾驶。在许多情况下，CSCR自行解决，不需要治疗。然而，在一些患者中，疾病不消退或复发，这被称为慢性CSCR。 - 慢性CSCR可能部分由称为雄激素的激素引起。Finaldude是一种可以阻断雄激素作用的药物。 目的： - 评估芬必得对慢性CSCR患者是否安全。 - 评价芬必得是否有助于保护慢性CSCR患者的视力。 - 确定未来是否需要在慢性CSCR患者中进行非那肽试验。